TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02267187
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
Study: NCT00408694
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01692301
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tablet
Study: NCT01692301
Drug: LCZ696 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 Matching Placebo tablet
Study: NCT01487200
Drug: FX006 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 3 mL IA injection
Study: NCT01487200
Drug: FX006 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 3 mL IA injection
Study: NCT01487200
Drug: FX006 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 3 mL IA injection
Study: NCT01487200
Drug: TCA IR 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 1 mL IA injection
Study: NCT03133260
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
Study: NCT03133260
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
Study: NCT02837783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, one daily
Study: NCT00920712
Drug: Weiqi decotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoction ,two times a day
Study: NCT02097147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, once per day.
Study: NCT04071184
Drug: Alofanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five dose cohorts and expanded cohort will be included
Study: NCT00037609
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 taken by mouth twice daily.
Study: NCT00520130
Drug: Conditioning Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3
Study: NCT00017862
Drug: SCH55700
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00480610
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT04223960
Drug: EA1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA1080 Formulation A.
Study: NCT04223960
Drug: EA1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA1080 Formulation B.
Study: NCT04223960
Drug: EA1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA1080 Formulation C.
Study: NCT04223960
Drug: EA1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA1080 Formulation D.
Study: NCT04223960
Drug: EA1080-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA1080-matching placebo.
Study: NCT04223960
Drug: EA1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA1080 Formulation E.
Study: NCT04223960
Drug: EA1080
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA1080 Formulation F.
Study: NCT00126087
Drug: dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004183
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00631137
Drug: testosterone gel applied to skin
Normalized name: testosterone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of testosterone gel
Study: NCT04455711
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of remifentanil 1.5 ng/ml until extubation
Study: NCT01014403
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle
Study: NCT01096563
Drug: AZD9164
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).~The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose.
Study: NCT01096563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation via Turbuhaler, JSMAD.
Study: NCT02711137
Drug: INCB057643
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
Study: NCT00389389
Drug: AZD4877
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00105443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib-matching placebo tablets were orally administered twice daily (bid).
Study: NCT02562742
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF 400 mg tablets administered orally once daily
Study: NCT00622895
Drug: Mycophenolic Acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00769119
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 30 mg, oral tablet, twice daily for 28 days
Study: NCT00769119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x Matched placebo, oral tablet, twice daily for 28 days
Study: NCT03887130
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
Study: NCT00650871
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00650871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00443391
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label study, subjects will take up to 80mg daily for 24 months.
Study: NCT00947076
Drug: Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00947076
Drug: Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00459420
Drug: Caffeine 100-200 mg BID
Normalized name: caffeine 200 MG
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
Study: NCT00459420
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00849576
Drug: Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
Study: NCT00849576
Drug: Insulin VIAject™ (75%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
Study: NCT00110773
Drug: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
Study: NCT00110773
Drug: Placebo Peel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
Study: NCT03016650
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
Study: NCT03016650
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
Study: NCT04512235
Drug: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to institutional standard of care.
Study: NCT03591458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
Study: NCT02625558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given three times a day
Study: NCT00706134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken once daily in the morning with a light meal.
Study: NCT01614132
Drug: maintenance chemotherapy (vincristin, cisplatin and CCNU)
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintenance chemotherapy of maximum of 8 cycles á 42 days
Study: NCT00545311
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00545311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03003104
Drug: DMT210 Topical Gel 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03316690
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2
Study: NCT03354754
Drug: LYS228
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYS228 IV infusion every 6 hours
Study: NCT01535781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical syringe and drip used as in the intervention, to ensure blinding.
Study: NCT00691483
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet taken orally twice daily for 12 weeks
Study: NCT01494363
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
Study: NCT03231176
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
Study: NCT01494363
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
Study: NCT03163420
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 50 mg granules for oral solution
Study: NCT00578643
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -5 through -2~50 mg/kg
Study: NCT01436539
Drug: Adefovir Dipivoxil and polyene phosphatidylcholine
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
Study: NCT00758862
Drug: 2% TD1414 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application 3 times daily for 7 days
Study: NCT02497001
Drug: Symbicort® Turbuhaler® (TBH) Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03566329
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion with the same rate of infusion as the study drugs
Study: NCT01737697
Drug: Placebo (acute phase)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
Study: NCT01737697
Drug: Placebo ( subacute phase)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
Study: NCT04340843
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00687518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of equivalent volume of saline serum
Study: NCT01514682
Drug: Anti-inflammatory Combination Therapy
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~2. fluvastatin: target dose 40 mg/day, administered in a single evening dose~3. combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose
Study: NCT01514682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-medication pills; To be taken in morning and evening intervals.
Study: NCT04421274
Drug: Best medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refer to the latest medication guidelines and give the best medication to the patients
Study: NCT00046774
Drug: MRA 003 US
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02755857
Drug: Lozanoc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg
Study: NCT01262365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Study: NCT02439125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. orally for 3 weeks
Study: NCT02507128
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo were taken 30 min before PCI.
Study: NCT00639249
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00829309
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg Tablet
Study: NCT00829309
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg Tablets
Study: NCT00781456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily to match experimental arm
Study: NCT04369365
Drug: Azithromycin 500 milligram (mg) oral Tablet
Normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: weekly oral use
Study: NCT04369365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly oral use
Study: NCT01148446
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/mq IV, day 1
Study: NCT01148446
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/mq IV, day 1
Study: NCT01148446
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/mq IV, day1
Study: NCT01441297
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 200mg bid, PO, daily until PD
Study: NCT00202462
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 7.5 gm qd
Study: NCT01568762
Drug: VAK694
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04434274
Drug: Micronized Purified Flavonoid Fraction
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
Study: NCT01568762
Drug: VAK694 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01568762
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01568762
Drug: QAX576 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00042874
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00042874
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04110847
Drug: JING CEIH SHERN YUAN EXTRACT PILL
Normalized name: Timothy grass pollen extract Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use, 3#BID
Study: NCT00835575
Drug: REMERON SolTab® 15 mg Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 15 mg, single-dose fasting
Study: NCT02792842
Drug: ART-123 (3-day ART)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART-123 380 U/kg infusion once daily on days 1-3 in each cycle
Study: NCT02792842
Drug: ART-123 (1-day ART)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART-123 380 U/kg infusion once on day 1 and placebo infusion once daily on days 2-3 in each cycle
Study: NCT05409339
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
Study: NCT05409339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
Study: NCT05095545
Drug: AV5080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsules with a white body
Study: NCT00160459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral Daily for 12 weeks
Study: NCT01837810
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800mg every 8 hours as needed for pain
Study: NCT03338998
Drug: BAF312 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous (IV) infusion - 4.5mg/4.5mL
Study: NCT03338998
Drug: Matching Placebo for BAF312 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo
Study: NCT03338998
Drug: BAF312 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg film-coated tablet
Study: NCT03338998
Drug: Matching Placebo for BAF312 tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg film-coated tablet matching placebo
Study: NCT00745836
Drug: statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00447941
Drug: SCA-136
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00514865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg QD(once a day) for 8 weeks
Study: NCT00003460
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT00620893
Drug: PEG- 400 based artificial tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
Study: NCT02450578
Drug: DSM265 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM265 400mg, single oral administration in a fed state
Study: NCT02450578
Drug: Placebo to DSM265 400 mg
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to DSM265 400mg, single oral administration in a fed state
Study: NCT00538239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 10 mg tablets taken by mouth for 5 days per week continuously
Study: NCT01695239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04067947
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet
Study: NCT02064387
Drug: GSK2857916
Approvals — FDA: no, EMA: no, PMDA: no
Description: A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
Study: NCT01532635
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
Study: NCT01269463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule without active drug
Study: NCT01232829
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01843179
Drug: Sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally twice per day at home for 12 months
Study: NCT02194244
Drug: RG1662 granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral administration of RG1662 immediate release granules
Study: NCT02194244
Drug: RG1662 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral administration of film-coated RG1662 immediate release tablet
Study: NCT01408446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule 48mg three times a day after meals 8 weeks
Study: NCT01220050
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for hyperparathyroidism for 26 weeks
Study: NCT03428724
Drug: Standard Preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
Study: NCT01014741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after PV isolation prior to CFE ablation.